Anhui Baker Biopharmaceutical Co., Ltd.

Main research purpose: According to the relevant provisions of bioequivalence test, the certified efamivir tablets (I) (trade name: SYMFI LO®, specification: each tablet contains 0.4g efavirenz, 0.3g lamivudine and 0.3g tenofovir disoproxil fumarate) of Mylan Pharmaceuticals Inc were selected as the reference preparation, and the test preparation efamivir tablets (I) (specification: each tablet contains 0.4g efavirenz, 0.3g lamivudine and 0.3g tenofovir disoproxil fumarate) produced by Anhui Baker Biopharmaceutical Co., Ltd. were subjected to fasting human bioequivalence test to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting conditions. Secondary study objective: To observe the safety of oral administration of the test preparation efamivir tablets (I) (specification: each tablet contains 0.4g efavirenz, 0.3g lamivudine and 0.3g tenofovir disoproxil fumarate) and the reference preparation efamivir tablets (I) (trade name: SYMFI LO®, specification: each tablet contains 0.4g efavirenz, 0.3g lamivudine and 0.3g tenofovir disoproxil fumarate) in healthy subjects.

Main research purpose: According to the relevant provisions of bioequivalence test, the dopamine tablets (trade name: Madopar®; specifications: 200 mg levodopa and 50 mg benserazide (equivalent to 57 mg benserazide hydrochloride)) produced by Shanghai Roche Pharmaceuticals Co., Ltd. were selected as the reference preparation, and the test preparation dopamine tablets (specifications: 200 mg levodopa and 50 mg benserazide (equivalent to 57 mg benserazide hydrochloride)) produced by Anhui Baker Biopharmaceutical Co., Ltd. were subjected to human bioequivalence test under fasting and postprandial administration conditions, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary study objective: To observe the safety of oral administration of the test preparation dobaserazide tablets (specifications: 200 mg levodopa and 50 mg benserazide (equivalent to 57 mg benserazide hydrochloride)) and the reference preparation dobaserazide tablets (trade name: Madopa®; specifications: 200 mg levodopa and 50 mg benserazide (equivalent to 57 mg benserazide hydrochloride)) in healthy volunteers.

Main research purpose: According to the relevant provisions of bioequivalence test, the zidovudine tablets (trade name: Combivir®, specification: each tablet contains 300 mg of zidovudine and 150 mg of lamivudine) produced by GlaxoSmithKline were selected as the reference preparation, and the test preparation zidovudine tablets (specification: each tablet contains 300 mg of zidovudine and 150 mg of lamivudine) produced and provided by Anhui Baker Biopharmaceutical Co., Ltd. were subjected to fasting and postprandial human bioequivalence test, to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary study objective: To observe the safety of oral administration of the test preparation Zidovudine Tablets (specification: each tablet contains 300 mg of zidovudine and 150 mg of lamivudine) and the reference preparation Zidovudine Tablets (trade name: Combivir®, specification: each tablet contains 300 mg of zidovudine and 150 mg of lamivudine) to healthy volunteers.